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SLEEP APNEA IN VETERANS WITH SCHIZOPHRENIA: ESTIMATING
PREVALENCE AND IMPACT ON COGNITION
Stephen Ghazikhanian and Toral Surti. Department of Psychiatry, Yale University,
School of Medicine, New Haven, CT.
Abstract:
The cognitive impairments of schizophrenia drive the functional disability of the illness
but are difficult to treat. One barrier to effective cognitive interventions may be medical
illnesses that compromise cognition and are over-represented in people with
schizophrenia. Obstructive sleep apnea (OSA) is treatable, causes reversible impairments
in many cognitive domains also affected by schizophrenia, and is likely under-diagnosed
in people with schizophrenia. We have estimated the prevalence of OSA in
schizophrenia, both by self-report and with a predictive model, and characterized the
associations between OSA and cognition and functional capacity in schizophrenia, using
a large dataset of 3942 patients with schizophrenia collected by the Veterans
Administration Cooperative Studies Program (CSP) #572 “Genetics of Functional
Disability in Schizophrenia and Bipolar Illness”. Neuropsychological tests included
TMT-A, BACS Symbol Coding, Category Fluency, verbal learning, working memory
and NAB Mazes. Functional capacity measures were the UCSD Performance Skills
Assessment Battery (UPSA-B) and the Everyday Functioning Battery- Advanced
Finances (EFB-AF). Phi correlations were used to assess associations of self-reported
OSA (R-OSA) with demographic and clinical factors. Self-reported diagnosis may
underestimate prevalence of OSA in this sample, so a clinical prediction model was also
used to calculate predicted prevalence of OSA (P-OSA). Each participant’s composite
cognitive score (CCS) was calculated by averaging their age- and gender-corrected T-
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scores for each cognitive test, with higher scores indicative of better performance. T-tests
compared assessments between reported and non-reported OSA (R-OSA v. nR-OSA) and
predicted and non-predicted OSA (P-OSA v. nP-OSA). ANOVAs were used to examine
differences in CCS, UPSA-B, and EFB-AF among R-OSA, predicted-and-not-reported
OSA (PnR-OSA), and No-OSA. Binary logistic regression models of PnR-OSA with
sociodemographic and clinical variables were used to characterize this vulnerable
subgroup. The reported prevalence of OSA was 14.4% (n=566). R-OSA patients were
more likely to have a college education, be married, and be functionally independent. The
predicted prevalence of OSA was 71.9% (n=2834). R-OSA patients had higher CCS than
nR-OSA, whereas P-OSA patients had lower CCS than nP-OSA (p’s<0.0002). R-OSA
patients performed better than nR-OSA in speed of processing assessments, whereas POSA individuals performed worse than nP-OSA in speed of processing, verbal learning,
and working memory (p’s<0.0005). R-OSA had higher UPSA-B and EFB-AF than nROSA (p’s<0.0001). P-OSA patients had a lower EFB-AF than those with nP-OSA (p=0.
003). PnR-OSA patients performed worse than both R-OSA and No-OSA on CCS and
EFB-AF, and worse than R-OSA on UPSA-B (p’s <0.05). Veterans with PnR-OSA
tended to be older, male, smokers, unmarried, and have higher BMI and less education
that the rest of the sample. Our analyses suggest only 20% of OSA in schizophrenia is
diagnosed. Self-reported OSA was associated with better performance on cognitive and
functional measures, whereas predicted OSA was associated with worse performance on
these measures. People with higher cognitive capacity may be more likely to seek
medical care, while those with less cognitive capacity are at greater risk for having co-
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occurring medical conditions that further compromise cognition. Patients vulnerable to
under-diagnosis likely have the most to gain from treatment of their OSA.
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INTRODUCTION
Cognitive Impairments and Resulting Disability in Schizophrenia
Schizophrenia, though only prevalent in under 1% of the population1, ranks
among the top 15 most disabling diseases in the world2. Adults with schizophrenia are
estimated to lose an average of 28.5 years of life compared to their healthy peers3 and are
significantly less likely to be employed (73-85% unemployed)4,5. These high rates of
disability and impairments in social and occupational functioning are marked by
persisting positive, negative, and affective symptoms, including suicidal ideation, and
cognitive impairments6,7. While psychotropic medications can treat positive symptoms
(such as delusions, hallucinations and thought disorganization), cognitive impairments
associated with schizophrenia (CIAS) have only shown small, if any, improvement with
these medications8,9 and have largely remained refractory to pharmacologic treatment10.
CIAS have also been shown to be detrimental to functional capacity11-13. Furthermore,
they are more strongly predictive of functional outcome than any other measurable
symptom, including psychotic symptoms11,14,15. CIAS are thus the primary cause of
disability in schizophrenia16.
CIAS are present in 70-75% of patients with schizophrenia17-19 and include
deficits in attention, working memory, episodic memory, processing speed and executive
function20-23. The ‘Measurement and Treatment Research to Improve Cognition in
Schizophrenia’ (MATRICS) initiative, a collaboration between experts in schizophrenia
and cognitive trials, led to the creation of the MATRICS Consensus Cognitive Battery
(MCCB), which measures performance with specific cognitive tests across the following
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seven domains: speed of processing, attention/vigilance, working memory, verbal
learning and memory, visual learning and memory, reasoning and problem solving, and
social cognition24-27, which is marked with difficulties in identifying emotions, feeling
connected to others, inferring people’s thoughts, and reacting emotionally to other28 .
Dysfunction across these domains in patients with schizophrenia is typically “moderately
severe” to “severe”, with patients performing 1.5–2.5 standard deviations below
neurotypical controls29,30.
The most striking CIAS are in speed of processing and working memory. Two
separate studies found these domains were most impaired in patients with schizophrenia
and associated with worse functioning30,31. One of the aforementioned studies found that
speed of processing and social cognition best distinguished patients with schizophrenia
from neurotypical controls29. The other showed that in addition to speed of processing
and working memory, attention/vigilance are distinctly worse in unemployed patients
with schizophrenia than patients who are able to maintain vocation30,31. A recent metaanalysis32 comparing 942 patients with schizophrenia to 899 healthy controls
corroborated deficits in all of these domains, highlighting more severe impairments in
patients with ‘deficit schizophrenia’, which is marked by primary, enduring negative
symptoms 32,33.
Cognitive Remediation Therapy (CRT), consisting of cognitive exercises and
training, remains the most effective treatment of CIAS, though it provides modest
improvements in cognition34,35. The most recent meta-analyses studying changes in CIAS
after CRT found effect sizes ranging between 0.18-0.2834, with no improvement noted in
visual memory, the smallest significant effect size in social cognition, and the largest
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significant effect in working memory. Known impairments in neuroplasticity of
schizophrenia36 may limit the efficacy of CRT; however, there likely remain other factors
that impair cognition and learning in schizophrenia. One set of relatively under-studied
and potentially modifiable such targets for treating CIAS are co-occurring nonpsychiatric illnesses that also impair cognition.

Obstructive Sleep Apnea: A Co-Morbidity with Common Cognitive Impairments
Several medical illnesses that compromise cognition are more prevalent in
schizophrenia than in the general population, including ischemic heart disease, stroke,
hypertension, obesity, diabetes, influenza/pneumonia, COPD and cancer37,38. These
illnesses reduce life-expectancy and quality of life and may also amplify and hinder
treatment of CIAS. Obstructive sleep apnea (OSA), a condition of sleep-disordered
breathing due to obstruction of upper airways and subsequent hypoxemia, is another such
co-occurring disorder that may be exacerbating the poor health outcomes, psychiatric
symptoms, cognitive deficits, and disability in schizophrenia39. OSA has been associated
with increased symptoms of depression and anxiety,40-42 hypothesized to be driven by a
multifactorial feedback pathways stemming from apneic episodes including sleep
fragmentation, pro-inflammatory and oxidative pathways resulting in neurotransmitter
imbalance, and sympathetic hyperactivity43. These same pathways may result in cognitive
impairments also seen in OSA.
Like schizophrenia, OSA is associated with cognitive impairments in the domains
of attention, verbal memory, executive function, psychomotor function, and visuospatial
memory44-47. The most recent and thorough analysis of cognition in OSA was a meta-
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review that considered seven studies (5 meta-analyses and 2 systematic reviews) with a
total of 6461 adults with OSA and 4932 healthy controls44. Their findings suggested
significant impairments in the following domains (with effect sizes reported in
parentheses): attention (0.58), memory (0.53), executive function (0.69), psychomotor
function (0.96) visuospatial/constructional function (0.69), and language function
(0.38)44. In this meta-review, speed of processing was a sub-domain of attention, and
executive functioning included assessments from the previously mentioned MCCB
(cognitive battery commonly used in schizophrenia) that assessed for working memory,
reasoning, and problem solving (i.e., Neuropsychological Assessment Battery (NAB)
Mazes & letter-number sequencing tests). Compared to healthy controls, patients with
schizophrenia had similar to more marked impairment across these domains: attention
(0.68-1.19), verbal memory (1.19-1.43), executive function (1.0-1.23), verbal fluency
(0.79-1.53), visual memory (0.78-1.17), processing speed (0.8-1.26), working memory
(1.0-1.04), and social cognition (0.84-1.44)32. A recent observational study found that
social cognition may also be impaired in patients with OSA, particularly those patients
with more prominent hypoxemia48. The significant similarities in cognitive dysfunction
are also associated with comparable neural changes in both diseases.

Neurobiological Changes Common to OSA And Schizophrenia
Patients with OSA and schizophrenia have common neurostructural and
neurofunctional abnormalities which have been associated with cognitive impairments. In
OSA, the neurobiological abnormalities and cognitive impairments are prominently
reversible when treated with positive airway pressure (PAP) during sleep.
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General gray matter volume (GMV) loss is common to both OSA and
schizophrenia. In OSA, decreased GMV in the anterior cingulate cortex
(ACC), hippocampus, frontal, parietal, and temporal lobes is associated with worse OSA
severity 45. Furthermore, reduced GMV in left hippocampus, left posterior parietal cortex,
and right superior frontal gyrus correlated with impairment in short-and long-term verbal
memory, constructional ability, attention, and executive function45. In schizophrenia,
similar regional reduction in gray matter and cortical thickness has been noted,
particularly in the hippocampus, frontal and temporal lobes; this has been negatively
correlated with improved cognition after CRT 49.
Brain structure is further changed by similar differences in white matter tract
integrity (WMI) in both OSA and schizophrenia. Diffuse reduction of WMI involving the
bilateral parietal and frontal lobes has been noted in OSA, and has been associated with
neurocognitive deficits involving attention, executive function, and memory 45. WMI
connecting prefrontal and temporal lobes has also been reduced in schizophrenia49,
although a recent large study (n=1963 patients with schizophrenia) showed similar
microstructural abnormalities throughout most major white matter regions in the brain50.
Functional connectivity is similarly changed in the aforementioned regions in
both diseases. For example, the default mode network (DMN), a large-scale brain
network primarily comprised of connections between the medial prefrontal cortex
(MPFC), posterior cingulate cortex (PCC) and angular gyrus, has been shown to have
reduced functional connectivity in both disorders51-54. Meta-analyses of resting state
connectivity of several brain networks noted widespread hypoconnectivity across key
hubs including the dorsolateral prefrontal cortex (DLPFC), ACC, cerebellum, MPFC,
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superior temporal gyrus (STG), hippocampus, PCC, amygdala, frontal pole (FP), nucleus
accumbens (NAcc), and postcentral gyrus (PCG) in schizophrenia 54. These global
reductions have been associated with worse processing speed, working memory, episodic
memory, attention, and verbal learning55. While this has been less thoroughly studied in
OSA, the existing evidence implicates common changes to these regions of interest and
their association with cognitive impairment. Most notably, a meta-analysis considering
functional changes of the brain in OSA similarly noted hypoactivation of the DLPFC
compared to healthy controls56. Furthermore, studies in OSA have shown negative
correlations between verbal memory and the connectivity of the PCC and hippocampus,
executive function and activation in the ACC and middle and inferior frontal gyri
(M/IFG), and overall cognition and functional connectivity in bilateral frontal poles,
middle temporal gyri, and hippocampi45,52,57-59.
Treating OSA and schizophrenia with continuous PAP (CPAP) and CRT,
respectively, does result in improvements and even normalization of these structural and
functional neural changes, though with varied effects. Cognitive impairments and mood
disturbances from OSA are treatable with CPAP, particularly in attention and vigilance
60-63.

A recent meta-analysis corroborated past work showing an improvement in attention

and speed of processing with an effect size of 0.1764. Others have also found
improvements in memory and executive function and tied it to neuroplastic changes in
the brain in as short as one month of treatment, specifically with hypertrophy and
increase in GMV of the thalamus, hippocampus, and frontal structures 62,65-67. With longterm use of CPAP, widespread changes in microstructural integrity of WM fiber tracts
have been noted; specifically, previous abnormalities appear reversible62,68,69. These
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changes appear far more robust than what has been studied in schizophrenia, especially
with regards to structural change. Many studies have provided evidence of increased
activation in the DLPFC, FP, ACC, PCG, M/IFG, and occipital regions during working
memory or executive function tasks after CRT 70-75. However, only two studies have
shown alterations in resting state functional connectivity between the frontal and
temporal lobes70,76,77. Furthermore, only two studies have reported CRT inducing
structural changes, specifically with GMV increases in the hippocampus, and only one
study has noted improved microstructural integrity in the genu and body of the corpus
callosum70,76,78,79. CPAP is shown to have a more robust impact on structural
normalization; this is important to note as studies have indicated that increased GMV,
specifically in frontal structures, are associated with better cognitive functioning after
CRT49. Thus, the use of CPAP may help enhance the outcomes of CRT in treating CIAS.
The under-utilization of CPAP is further emphasized when we consider prevalence of
OSA in patients with schizophrenia.

Co-occurring OSA in Schizophrenia Deserves Further Study
OSA in schizophrenia is not well-studied, and findings indicate it may be underrecognized and under-treated. Recent estimates of OSA prevalence in schizophrenia
range from 14.9&-40%80-82, though past studies have found prevalence is as wide as 0.757.1%83-85. This range extends above the estimated 9-38% prevalence of OSA seen in the
general population86. The largest population-based study of association between OSA and
patients with serious mental illness was done by extracting diagnoses from electronic
medical records of the Veteran population; it found a prevalence of OSA of 2.9% in the
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general population and 4.52% in patients with psychosis87. A meta-analysis of OSA in
serious mental illness did not have sufficient data to compare prevalence of OSA in
schizophrenia to the general population88. Thus, more work is needed to further elucidate
prevalence of OSA in schizophrenia.
Studies have shown that patients with schizophrenia may be at higher risk of
developing OSA, and that OSA may be underrecognized. A Taiwanese national cohort
study (n=5092) found a nearly two-fold increased risk of developing OSA amongst
people with schizophrenia compared to age-matched control participants even after
controlling for gender, age, comorbidities and duration of antipsychotic use 89. A crosssectional cohort study found that 57% of their sample of patients with schizophrenia were
at high-risk for OSA based on symptom-related screening, though less than a quarter of
these patients had received a prior diagnosis80. The true rate of OSA in schizophrenia is
likely under-estimated due to under-diagnosis and increased risk of OSA development.
Though the effects of treating OSA on CIAS are grossly under-studied, the
theoretical considerations above and one small study suggest that cognition can improve
with OSA treatment in patients with co-occurring OSA. One study of 6 patients with
schizophrenia has shown that treatment of OSA with CPAP improves CIAS 90. In this
sample, OSA treatment with CPAP resulted in a 0.59 Z score improvement in global
cognition, with the most notable improvements in working memory (0.71 Z score
improvement on digit sequencing) and motor speed (0.66 Z score improvement on token
motor task)90. Thus, untreated OSA may be limiting the full potential improvements of
CIAS, though many questions remain as to how these two disorders synergistically affect
cognitive functioning and cognitive recovery.
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Our study aims to understand the role of OSA in contributing to cognitive deficits
and functional impairments in schizophrenia. To do this, we analyzed a data-set of 3942
Veterans with schizophrenia collected through the Veterans Affairs Cooperative Studies
Program (CSP)# 57291. This dataset includes clinical ratings, cognitive assessments,
measures of community functioning, and thorough medical histories. In this study, we
describe the prevalence of reported OSA in this sample and use a clinical prediction
model developed by Ustun et al.,92 to calculate the predicted prevalence of OSA in the
cohort. Then we studied the associations of reported and predicted OSA with cognition
and functioning based on performance on a subset of the MCCB and standardized
assessments of community functioning. Exploratory analyses included analyzing
performance and predicting characteristics of patients who have predicted-but-unreported
(and thus untreated) OSA. This work aims to characterize the contribution of OSA, a
treatable condition, to CIAS and disability in schizophrenia.
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STATEMENT OF PURPOSE
The cognitive impairments in schizophrenia have been nearly refractory to treatment,
though they are largely responsible for the functional disability of the illness. In this
study, we examined a pre-existing dataset to explore whether a co-occurring and treatable
medical condition, obstructive sleep apnea (OSA), may be contributing to these cognitive
and functional impairments, suggesting a strategy to improve community functioning in
schizophrenia. The goal of this thesis is to estimate: 1) the prevalence of obstructive sleep
apnea (OSA) in schizophrenia, and 2) the effects of OSA on cognition and functioning in
schizophrenia, specifically within the Veteran population. This is accomplished through
the following aims and, when appropriate, hypotheses.
Specific Aims:
1.

Prevalence of OSA in Schizophrenia:
a. Describe the prevalence of self-reported OSA diagnosis in this sample of
Veterans with schizophrenia.
b. Characterize associations of reported OSA diagnosis with significant
sociodemographic and clinical measures.
c. Use a clinical prediction model of OSA to estimate the prevalence of OSA
in Veterans with schizophrenia and compare this estimated prevalence to
that determined by patient report.
Hypothesis: OSA will be under-diagnosed in this sample i.e., the clinical
prediction model will identify significantly more patients with predicted
OSA than those who reported OSA diagnosis.
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2. Association of OSA and Cognition in Schizophrenia:
a. Compare global cognitive function in those with reported OSA (R-OSA)
to those who did not report OSA (nR-OSA).
Hypothesis: Patients with R-OSA will have poorer cognitive functioning
than those with nR-OSA.
b. Compare global cognitive function in those with predicted OSA (P-OSA)
to those without predicted OSA (nP-OSA).
Hypothesis: Patients with P-OSA will have poorer cognitive functioning
than those with nP-OSA.
c. Examine the association of OSA on specific cognitive domains in
Veterans with schizophrenia.
Hypothesis: Cognitive functioning will be poorer in patients with R-OSA
and P-OSA in the following domains: speed of learning, verbal learning,
and reasoning and problem-solving.

3. Association of OSA and Functional Capacity in Schizophrenia:
a. Compare performance on functional measures in those with R-OSA to
those with nR-OSA.
Hypothesis: Patients with R-OSA will have poorer performance on
functional measures than those with nR-OSA.
b. Compare performance on functional measures in those with P-OSA to
those with nP-OSA.

12

Hypothesis: Patients with P-OSA will have poorer performance on
functional measures than those with nP-OSA.

Exploratory Aims:
1. Examine differences in cognition and functioning in patients with R-OSA and
undiagnosed OSA (i.e., predicted-and-not-reported OSA or PnR-OSA).
2. Describe differences in sociodemographic and clinical characteristics of patients
with PnR-OSA and R-OSA.
3.

Estimate the effect of treated versus untreated OSA on cognition and functioning
in the subsample of Veterans with schizophrenia that reported OSA.
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METHODS
Student Contributions:
All data, including demographic and clinical characteristics and cognitive and functional
measure performance, were previously collected as part of the Cooperative Studies
Program (CSP) #572 study91 and were provided to TS and SG de-identified. The study
was conceived by TS. SG was responsible for further data processing by creating binary
variables from the following ordinal or nominal variables: “marital status” to “married”,
“level of education” to “college education”, “income” to “low-income” (i.e., <$20,000
annual income), “residential status” to “independent living”, and “employment status” to
“employed”. SG converted raw performance on various normed neuropsychological
assessments to age-and-gender-corrected T-scores with the MATRICS software. Data
processing included creating the following new variables from this dataset: “BMI” based
on height and weight93, a binary “predicted-OSA” variable based on calculation from a
clinical prediction model92, “Completeness” based on each participants rate of
completing the required components of questionnaires, and a “Composite Cognitive
Score (CCS)” which was an average of T-scores from each cognitive assessment per
participant. An additional variable marking those patients who were predicted to have
OSA but did not report having OSA (PnR-OSA) was also created. All statistical analyses,
described below, were designed and completed by SG with some feedback from a
consulting statistician and TS. All initial manuscript and figure authorship was completed
by SG with editing and feedback provided by TS.

Ethics Statement:
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This study was supported by Yale School of Medicine Fellowship for Medical Student
Research and Richard K. Gershon Endowed Medical Student Research Fellowship
awarded to SG. There are no conflicts of interest to report. This study does not contain
any studies involving animals performed nor does it involve direct work with human
participants. Data was initially collected with human participants and as such all
procedures performed were in accordance with the ethical standards of the institutional
and/or national research committee and with the 1964 Helsinki Declaration and its later
amendments or comparable ethical standards. Informed consent was obtained from all
individual participants involved in the study91.

Human Subjects Research:
Veterans Affairs Connecticut Healthcare System Research & Development Committee
and the Cooperative Studies Program (CSP) #572 Executive Committee approved use of
this de-identified data. All research participants provided informed consent to both
immediate and long-term goals of the CSP#572 repository at the time of data collection
and provided written consent for use of de-identified data for future studies related to
schizophrenia and bipolar disorder, such as the present study.

Methods Description: Participants, Measures, & Procedures
Data Processing and data analysis were performed on de-identified data that was initially
collected from Veterans who participated in the CSP#572: Genetics of Functional
Disability in Schizophrenia and Bipolar Illness study 91.
Participants:
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Veterans with schizophrenia and bipolar disorder were recruited for the multicenter
CSP#572 study between 2011-2014. Patients of VA medical centers were identified with
medical record information or referred by their clinicians. Potential participants were then
sent an invitational mailing from local site investigators to assess their interest in
participating in a VA research study. Diagnosis of schizophrenia or bipolar disorder was
confirmed with the Structured Clinical Interview for DSM-IV (SCID)94. Participants
completed questionnaires to provide demographic information and medical history,
including the presence of other medical or psychiatric diagnoses. Neuropsychological
testing and assessments of functional capacity were administered in person. The data
from the 3942 Veterans with confirmed schizophrenia were included in these analyses.
Measures & Procedures:
Demographic Data: The following variables were included in our analyses: age, gender
(male or female), race (White, Black, American Indian, Other), marital status (married or
non-married), education level (no college or any college), low-income (<$20,000 or not),
employment status (employed or unemployed), and residential status (independently
living or not, e.g., unsupervised residential facility or supervised residential facility)
Clinical Characteristics: The following variables were included in our analyses: bodymass index (BMI), self-reported medical history (including diseases related to circulatory
system, mental health, musculoskeletal health, hearing/vision problems, infectious
disease, cancer, gastrointestinal disorders, renal issues, nervous system problems,
endocrine disorders, pulmonary disorders, substance use including tobacco and alcohol,
and other conditions, like OSA), self-reported number of prescription medications, and
hospitalizations. Specific conditions per organ system were listed and Veterans were
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asked to fill in a circle if they had the condition, write out the year in which they were
diagnosed, and fill in a circle if they took any medications for the condition. The
conditions were presented under subheadings as such: Circulatory Problems (“High
Blood Pressure (Hypertension),” “Stroke,” “Transient Ischemic Attack (TIA),” “Heart
Attack,” “Coronary Artery Disease/Coronary Heart Disease (includes angina),”
“Peripheral Vascular Disease,” “High Cholesterol,” “Pulmonary Embolism or Deep Vein
Thrombosis (DVT),” “Congestive Heart Failure,” “Other Circulatory Problem”), Mental
Health Disorders (“Anxiety reaction/Panic disorder,” “Attention deficit hyperactivity
disorder (ADHD),” “Bipolar disorder,” “Post-traumatic stress disorder (PTSD),”
“Depression,” “Eating disorder,” “Personality disorder,” “Schizophrenia,” “Social
Phobia,” “Other mental health disorder”), Skeletal/Muscular Problems (“Osteoarthritis,”
“Rheumatoid arthritis,” “Other arthritis,” “Gout,” “Osteoporosis,” “Other
skeletal/muscular problem”), Hearing/Vision (“Cataracts,” “Glaucoma,” “Macular
degeneration,” “Blindness, all causes,” “Tinnitus or ringing in the ears,” “Severe hearing
loss or partial deafness in one or both ears”), Infectious Diseases (“Tuberculosis,”
“Hepatitis C,” “HIV/AIDS,” “Other infectious disease”), Cancer (“Breast cancer,”
“Colon cancer/rectal cancer,” “Lung cancer,” “Prostate cancer,” “Skin cancer,” “Other
cancer”), Kidney Disease (“Kidney disease without dialysis,” “Kidney disease with
dialysis,” “Acute kidney disease with no dialysis”), Digestive System Problems (“Acid
reflux/GERD,” “Peptic ulcers,” “Bowel obstruction,” “Colon polyps,” “Irritable Bowel
Syndrome (IBS),” “Ulcerative colitis,” “Crohn’s disease,” “Celiac disease/ sprue,”
“Other digestive system disorder”) Nervous System Problems (“Migraine headaches,”
“other headaches,” “Memory loss or impairment,” “Dementia (includes Alzheimer’s,
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vascular, etc.),” “Concussion or other loss of consciousness,” “Traumatic brain injury,”
“Spinal cord injury or impairment,” “Epilepsy/seizures,” “Parkinson’s disease,”
“Amyotrophic lateral sclerosis (Lou Gehrig’s disease),” “Multiple sclerosis,” “Other
nervous system problem”), and Other Conditions (“Asthma,” “Chronic lung disease
(COPD, Emphysema or Bronchitis),” “Diabetes/ ‘sugar’,” “Enlarged prostate (Benign
prostatic hyperplasia),” “Liver condition (e.g., cirrhosis),” “Skin condition (e.g., eczema,
psoriasis),” “Sleep apnea,” “Thyroid problems,” “Other disease/disorder”). Number of
prescriptions and number of hospitalizations were ordinal variables represented by the
following ranges: 0, 1-3, 4-6, 7-9, 10-15, 15 or more.
Neuropsychological (NP) assessment: The following assessments, which are wellnormed, validated and included in the MATRICS Consensus Cognitive Battery25, were
used as measures of cognitive functioning in the following domains: speed of processing
(Trail-making part A, the Brief Assessment of Cognition in Schizophrenia, BACS,
Symbol Coding subtest, Category Fluency-animal naming), verbal learning (the Hopkins
Verbal Learning Test, HVLT), working memory (Weschler Adult Intelligence Scale -III
WAIS-III Letter-Number Sequencing,) and reasoning and problem-solving
(Neuropsychological Assessment Battery, NAB, mazes test). Trail-making part A95 is a
timed paper-and-pencil test in which the respondent draws a line to connect consecutively
numbered circles placed irregularly on a sheet of paper. BACS symbol coding96 is a
timed paper-and-pencil test in which the respondent uses a key to write digits that
correspond to nonsense symbols. The category fluency97 task is an oral test in which the
respondent names as many animals as she/he can in 1 minute. The HVLT98 is an orally
administered assessment of verbal memory in which a list of 12 words from three
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taxonomic categories is presented and the respondent is asked to recall as many as
possible after each of three learning trials. The WAIS-III Letter-Number Sequencing
assessment99 is an orally administered test in which the respondent mentally reorders
strings of number and letters and repeats them to the administrator. The NAB mazes
test100 includes seven timed paper-and-pencil mazes of increasing difficulty that measure
foresight and planning. Raw scores for each assessment were age-and-gender corrected to
T-scores, ranging from 0 to 100. A composite cognitive score (CCS) was calculated by
averaging the age-and-gender corrected t-scores of each neuropsychological assessment
for each participant.
Functional capacity: Two tests were administered to assess functional capacity:
University of California San Diego (UCSD) Performance Skills Assessment -Brief
(UPSA-B) and the Everyday Functioning Battery- Advanced Finances (EFB-AF). The
UPSA-B101 asks patients to perform everyday tasks related to communication and
finances. During the Communication subtest, participants role-play exercises using an
unplugged telephone (e.g., emergency call; dialing a number from memory; calling to
reschedule a doctor’s appointment). For the Finance subtest, participants count change,
read a utility bill, and write a check for the bill. Raw scores were reported on a scale of 0
to 20. The EFB-AF102 requires individuals to prepare bank deposits, write checks to pay
bills, maintain a checkbook balance, and organize payments such that a pre-specified
amount of money is left available at the end of the task. Raw scores were reported on a
scale of 0 to 13. Both these tests have high correlation to cognitive performance and
everyday functional disability in schizophrenia 103,104.
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Negative symptoms: Avolition (reduced motivation and activity), alogia (reduced verbal
output), and affective flattening were assessed by trained research staff at the time of the
diagnostic assessment with the use of SCID items, rated based on present/absent criteria.
Posttraumatic stress disorder (PTSD): The PTSD module from the MINI International
Diagnostic interview105 was used as the assessment instrument, examining the presence
of current (i.e., last 6 months) of PTSD.
Major depression: SCID was used to examine the lifetime history of a major depressive
episode.
Assessment of suicidality: The Columbia Suicide Severity Rating Scale106 was
administered to assess suicidal ideation, suicide attempts, and severity of suicidality.
Clinical Prediction Model: We used a model published by Ustun et al., 201692 that was
generated using Supersparse Linear Integer Models (SLIM) machine learning method for
creating a medical scoring system. This scoring system relied on ten extractable features
based on age, BMI, gender, smoking status, and history of hypertension and diabetes
Those who scored greater than 29 points were predicted to have OSA with a false
positive rate of approximately 20%. Age comprised two greater than or equal to 30
scored 16 points and greater than or equal to 60 scored an additional 16 points. BMI
greater than or equal to 25 scored 12 points, greater than or equal to 30 scored 2
additional points, greater than or equal to 35 an addition 10 points, and greater than or
equal to 40 an additional 4 points. History of diabetes scored 6 points, history of
hypertension scored 4 points, current smoking status scored 2 points. Female gender
scored a reduction of 14 points.
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The True Positive Rate (TPR) or sensitivity for this model was 64.2% (58.6-69.1% range)
and False Positive Rate (FPR) was 23.0% (15-30.6% range).

Statistical Methods:
Specific Aim #1: Descriptive statistics were used to determine the prevalence of selfreported OSA (R-OSA) in the CSP#572 dataset of Veterans with schizophrenia, in
addition to exploring the demographic and clinical characteristics of Veterans with both
diseases. To further describe R-OSA in this population, multiple Chi-Square tests and Phi
correlations with Bonferroni’s correction were performed to assess the association of
OSA with the following variables: age, gender, race, marital status, education level,
income, body-mass index (BMI), medical and psychiatric comorbidities, independent
living/residential status, polypharmacy, and hospitalization frequency. Use of the clinical
prediction model identified Veterans predicted to have OSA and descriptive statistics
were used to estimate prevalence. A Mcnemar’s test was used to compare proportion of
predicted OSA (P-OSA) and R-OSA. All comparisons between R-OSA and not-reported
OSA (nR-OSA) were corrected for multiple comparisons (n=100) with Bonferroni’s
correction and evaluated with a p<0.0005 accordingly; this includes the aforementioned
Phi correlation, chi-square tests, and subsequent T-tests.
Specific Aim #2: Composite Cognitive Scores (CCS) were examined for normal
distribution by visualization and the Shapiro-Wilk test. Two-sided T-tests compared
mean CCS in participants with reported and not-reported OSA (R-OSAv. nR-OSA) and
predicted and not-predicted OSA (P-OSA v. nP-OSA), followed by calculation of effect
sizes (Cohen’s d). All comparisons between P-OSA and nP-OSA were corrected for
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multiple comparisons (n=10) with Bonferroni’s correction and evaluated at a p<0.005.
Then, to determine the unique association between reported OSA and cognition, a
univariate linear regression predicting CCS with the study variable of OSA (e.g., R-OSA)
and multivariate models with additional independent variables were performed. These
additional variates included pre-identified variables associated with cognitive
performance and OSA, including age, gender, education, income, race, number of
prescriptions and hospitalizations, cardiovascular, neurological, and psychiatric
comorbidities. ‘Completeness’, a measure of completeness of required sections for each
participant’s questionnaire, was also included to serve as an adjustment for limitations
with self-report and possible confounder in measures of cognition and functioning.
Additionally, variables that had a statistically significant Phi Coefficients > 0.1 with ROSA from specific aim #1 were included as independent variables. The same series of
analyses, including two-sided T-tests and linear regressions, were performed to study the
associations of P-OSA with cognition. Finally, two-sided T-tests were used to compare
mean scores of each neuropsychological test between R-OSA v. nR-OSA and P-OSA v.
nP-OSA, with subsequent calculation of effect sizes (Cohen’s d).
Specific Aim #3: UPSA-B and EFB-AF scores were both be examined for normality in
the same manner as above. Two-sided Mann-Whitney U tests were used to compare
means between the groups R-OSA v. nR-OSA as well as P-OSA v. nP-OSA. Univariate
and multivariate linear regressions predicting performance on each functional capacity
measure (i.e., UPSA-B and EFB-AF) were performed with the aforementioned
independent variables from specific aim #2 to estimate the unique association between
OSA (i.e., R-OSA and P-OSA) and functional capacity.
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Exploratory Aims: ANOVA was used to compare means of CCS, UPSA-B, and EBF-AF
across three groups: R-OSA, those with predicted and unreported OSA (PnR-OSA), and
those without predicted or reported OSA (No-OSA), at p<0.016; Tukey HSD post-hoc
tests were used to compare mean differences between these three groups (R-OSA v. PnROSA v. No-OSA), with a p<0.0028. Binary Logistic Regression was used to model PnROSA and R-OSA with sociodemographic and diagnostically verified clinical
characteristics as the independent variables; statistically significant predictors of PnROSA and R-OSA were reported as adjusted Odds-Ratio (aOR). Finally, CCS and
functional assessments scores of the subsample of Veterans with R-OSA were compared
with two-sided T-tests (p <0.016) with reported treatment as the independent variable.
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RESULTS:
Specific Aim # 1: Prevalence of OSA in Schizophrenia
A total of 566 patients (14.4%) from our sample of 3942 Veterans with
schizophrenia reported OSA (R-OSA). Table 1a describes sociodemographic data for this
sample compared to Veterans who did not report OSA (nR-OSA). R-OSA patients were
more likely to have gone to college, be married, and live independently.

Table 1a: Sociodemographic Characteristics of Participants with Reported OSA
Reported OSA

Did Not Report OSA

p-values

(R-OSA)

(nR-OSA)

(only <0.05)

Male (%)

527 (93.3%)

3117 (92.6%)

Mean age (SD)

56 (8.45)

54.95 (10.33)

Race-White (%)

230 (40.6%)

1323 (39.2%)

Race-Black/African-

296 (52.3%)

1862 (55.2%)

American-Indian (%)

32 (5.7%)

139 (4.1%)

Race-Other

40 (7.1%)

160 (4.7%)

0.02

No College

187 (33.2%)

1522 (45.3%)

9.6105E-8*

Married

146 (25.9%)

546 (16.3%)

2.8067E-8*

Employed

51 (9.0%)

321 (9.5%)

Living Independently

408 (72.1%)

2116 (63.0%)

0.000028*

Low Income

224 (39.8%)

1542 (46.2%)

0.004

0.009

American (%)
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* denotes p<0.0005, adjusting for multiple comparisons; SD-Standard Deviation

Table 1b describes clinical information gathered from a diagnostic interview in ROSA and nR-OSA patients. Veterans with R-OSA were more likely to have PTSD, a
history of MDD, and a history of suicidal ideation and suicide attempt.

Table 1b: Diagnostic Characteristics of R-OSA and nR-OSA
R-OSA

nR-OSA

p-values
(only <0.05)

PTSD-MINI (%)

187(33.1%)

682 (20.2%)

9.1333E-12*

MDD-SCID (%)

308 (54.6%)

1318 (39.2%)

5.7704E-12*

Avolition-SCID (%)

251 (44.6%)

1479 (43.9%)

Alogia- SCID (%)

167 (29.6%)

1203 (35.7%)

Flat Affect- SCID (%)

256 (45.4%)

1600 (47.5%)

Suicidal Ideation- CSS

419 (74%)

2079 (61.7%)

1.865E-8*

261 (46.6%)

1296 (38.7%)

0.000410*

0.005

(%)
Past Suicide Attempt (%)

* denotes p<0.0005, adjusting for multiple comparisons
Abbreviations: R-OSA – Reported OSA; nR-OSA- did not report OSA; PTSD- Post Traumatic Stress
Disorder; MINI- Mini International Neuropsychiatric Interview; MDD- Major Depressive Disorder; SCIDStructured Clinical Interview for DSM-IV;

Table 1c describes those variables that are a part of the clinical prediction model
developed by Ustun et al (2016)92 in R-OSA and nR-OSA. Veterans with R-OSA were
more likely to have higher BMI, hypertension, diabetes, and be non-smokers.
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Table 1c: Medical Characteristics of R-OSA
R-OSA

nR-OSA

p-values
(only <0.05)

Age (SD)

56.00 (8.45)

54.95 (10.33)

0.009

BMI (SD)

33.11 (7.21)

28.63 (5.74)

6.1452E-39*

Male (%)

527 (93.3%)

3117 (92.6%)

Hypertension (%)

412 (72.8%)

1732 (51.3%)

6.0046E-22*

Diabetes (%)

237 (41.9%)

770 (22.8%)

4.2422E-20*

Smoker (%)

273 (48.9%)

1971 (58.7%)

0.000017*

* denotes p<0.0005, adjusting for multiple comparisons
Abbreviations: R-OSA – Reported OSA; nR-OSA- did not report OSA, SD-Standard Deviation

Strong correlations (Phi’s Coefficient >0.15) were found between R-OSA and
number of prescription medications (Phi’s Coefficient = 0.207), depression (0.166),
GERD (0.163), anxiety and panic disorders (0.162), memory loss (0.158), type 2 diabetes
(0.153), hypertension (0.151), p<0.0005. Moderate correlations were found between ROSA and tinnitus (0.141), migraines (0.125), COPD (0.125), benign prostatic hyperplasia
(0.124), PTSD (0.123), high cholesterol (0.121), osteoarthritis (0.118), hearing loss
(0.115), rheumatoid arthritis (0.113), other arthritises (0.108), and gout (0.107),
p<0.0005. Weak correlations (Phi’s Coefficient >0.05, p<0.0005) were found between ROSA and personality disorder (0.097), bowel obstruction (0.097), irritable bowel
syndrome (0.097), TBI (0.097), coronary artery disease (0.096), loss of
consciousness(0.094), asthma(0.092), heart attack (0.090), bipolar disorder (0.082),
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eating disorder( 0.082), polyps (0.080), spinal cord injury or impairment (0.075),
peripheral vascular disease (0.074), gastrointestinal ulcers(0.074), current smoker (0.069), social anxiety disorder (0.065), cataracts (0.065), acute renal failure (0.063),
macular degeneration( 0.063), kidney disease not requiring dialysis( 0.062), stroke
(0.062), frequency of hospitalizations( 0.062), and pulmonary embolism/deep venous
thrombosis (DVT) (0.061).
Using the clinical prediction model developed by Ustun et al.92, we identified
Veterans predicted to have OSA versus those unlikely to have OSA. 138 Veterans,
including 27 Veterans with R-OSA, were excluded from this and future analyses
involving predicted v. unpredicted OSA due to missing data-points needed for this
prediction. The estimated prevalence of OSA in this sample was 71.9% (n=2834). A
Mcnemar’s test to compare proportions of P-OSA and R-OSA found a statistically
significant difference (Z=46.51, p=0.0E0) in these rates, such that 60.3% of the sample
had predicted and not reported OSA, 95% confidence interval (CI) [58.7%, 62.0%].
Figure 1 demonstrates the number of Veterans with P-OSA v. nP-OSA split by whether
they reported or did not report OSA. This highlights that 83.5% of patients with P-OSA
did not in fact report having the condition. However, 87% of patients with R-OSA also
had P-OSA.
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Figure 1: Predicted v. Reported OSA Contingency Graph
There were 469 Veterans with R-OSA and P-OSA from a total of 2,834 Veterans with P-OSA. Only 70
Veterans with R-OSA also had nP-OSA with a total of 970 Veterans with nP-OSA.

Specific Aim #2: Association of OSA and Cognition in Schizophrenia
We next sought to determine whether cognitive performance differed in R-OSA
versus nR-OSA and P-OSA versus nP-OSA. The mean age- and gender- adjusted global
composite cognitive scores (CCS) were significantly higher in R-OSA (mean = 37.61;
standard deviation SD = 7.21) than in nR-OSA (mean = 36.27, SD = 7.77; p= 0.000159).
The difference between R-OSA and nR-OSA GCC means was 1.33 T-Scores, 95% CI
[0.64, 2.03]). The Cohen’s d effect size was 0.174, 95% CI [0.084, 0. 264]. Figure 2
shows the distribution of CCS in R-OSA and nR-OSA.
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Figure 2: Distribution of Composite Cognitive Score in Reported & Non-Reported OSA
In R-OSA, the median was 36.33 with an interquartile range of 10.17. The minimum score was 8.67 and
the maximum was 67.33. In nR-OSA, the median was 37.83 with an interquartile range of 10.46. The
minimum score was 13.00 and the maximum was 56.50.

While cognitive performance was better in R-OSA than in nR-OSA, CCS in POSA was lower than in nP-OSA (p= 0. 000010; Cohen’s d = -0.171, 95% CI [-0.244, 0.098]). The mean and standard deviation of CCS for P-OSA and nP-OSA were 36.15
(7.74) and 37.46 (8.04), respectively. The mean difference between P-OSA and nP-OSA
CCS was -1.31, 95% CI [-1.89, -0.73]. Figures 3 depicts the distribution of CCS for POSA and nP-OSA Veterans.

29

Figure 3: Distribution of Composite Cognitive Score in Predicted & Non-Predicted OSA
In P-OSA, the median was 36.17 with an interquartile range of 10.00. The minimum score was 8.67 and the
maximum was 65.00. In nP-OSA, the median was 37.67 with an interquartile range of 10.67. The minimum
score was 12.17 and the maximum was 59.33.

Linear regression analyses were then performed to study the relationship between
OSA and CCS. R-OSA had a standardized coefficient (or Beta) of 0.061 (p= 0.000159) in
association with CCS in univariate analyses, while P-OSA had a standardized coefficient
(or Beta) of -0.074 (p=0.000005) in association with CCS. R-OSA maintained a
significant association with CCS (B= 0.037, p=0.02) even after controlling for
sociodemographic and medical variables; P-OSA did not maintain a statistically
significant relationship in multivariate analyses. Table 3 reports multivariate linear
regressions predicting CCS with R-OSA and P-OSA as the study variables in addition to
statistically significant covariates.
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Table 3: Linear Regression of CCS with Reported & Predicted OSA as Study Variable

R-OSA
P-OSA
Age
BMI
Completeness
Female
White
College
Living
Independently
Employed
Suicidal Ideation
Alogia
Flat Affect
Number of
Hospitalizations
Number of
Prescriptions
Hypertension
Rheumatoid
Arthritis
Memory Loss
Benign Prostatic
Hyperplasia
Depression
Bipolar Disorder
Personality
Disorder
Social Phobia
Stroke
Skin Cancer
Loss of
Consciousness
Epilepsy
Drinks Alcohol

Beta in
Univariate Model
with R-OSA
0.061**

Beta in Multivariate
Model
With R-OSA
0.036

Beta in
Univariate Model
with P-OSA

Beta in
Multivariate
Model with P-OSA

-0.074**
-0.144**
0.034
0.036
0.041
0.045
0.188**
0.140**

----0.150**
---0.036
0.044
0.044
0.189**
0.141**

0.063**
0.070**
-0.094**
-0.060**
-0.030

0.064**
0.071**
-0.094**
-0.061**
---

-0.141**

-0.140**

-0.033
-0.032

-0.035
-0.031

-0.060**
0.043

-0.059**
0.045

--0.052**
0.043

0.033
0.052**
0.043

0.032
-0.034
0.043
0.050

0.032
-0.034
0.042
0.051

-0.033
0.032

-0.033
0.033

Italicized variables are medical variables based on self-report by patient.
Only statically significant variables are listed above; other variables included in multivariate model
include: Married, MINI-PTSD, SCID-MDD, Suicide Attempts, Avolition, Current Smoker, Dementia, TBI,
High Cholesterol, TIA, Osteoarthritis, Other arthritises, Gout, Anxiety, self-reported PTSD, Eating
Disorder, ADHD, GERD, Tinnitus, Hearing Loss, Blindness, Glaucoma, Macular Degeneration, COPD,
Diabetes, Colon Cancer, Lung Cancer, Breast Cancer, Prostate Cancer, Other Cancers, Parkinson’s
Disease, Non-Migraine Headaches, Migraines, Amyotrophic Lateral Sclerosis, Multiple Sclerosis,HIV.
** denotes a p-value <0.001
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In considering specific neuropsychological tests, Table 4 compares the mean Tscores and standard deviations between R-OSA and nR-OSA for each assessment.

Table 4: Specific Neuropsychological Test Performance in R-OSA v. nR-OSA
R-OSA

nR-OSA

p-value (only <0.05)

TMT-A (SD)

36.27 (12.46)

35.20 (13.11)

---

BACS SC (SD)

35.69 (11.29)

33.76 (11.74)

0.000345*

Category Fluency

41.51 (9.77)

39.89 (10.14)

0.000470*

HVLT (SD)

35.10 (7.08)

34.39 (7.49)

0.037

LNS (SD)

35.28 (11.91)

33.36 (12.63)

0.000511

NAB Mazes (SD)

42.19 (7.98)

41.53 (8.26)

----

(SD)

* denotes p<0.0005, adjusting for multiple comparisons
Abbreviations: R-OSA – Reported OSA; nR-OSA – did not report OSA; TMT-A – Trail-making test part
A; BACS SC- Brief Assessment of Cognition in Schizophrenia Symbol Coding Subtest; HVLT- Hopkins
Verbal Learning Test; LNS- Letter-Number Sequencing; NAB – Neuropsychological Assessment Battery;

The mean difference between R-OSA & nR-OSA BACS SC T-score was 1.92 (95% CI
[0.87, 2.98]), with T-scores in R-OSA being statistically significantly higher than in nROSA (p=0.000345); Cohen’s d was 0.165, 95% CI [0.074, 0.255]. The mean difference
between R-OSA & nR-OSA Category Fluency T score was 1.62 (95% CI [0.71, 2.53]),
with T-scores in R-OSA being statistically significantly higher than in nR-OSA (p=0.
000470); Cohen’s d was 0.161, 95% CI [0.071, 0.251]. Figure 4 illustrates average T-
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scores for each test, denoting statistically significant differences between the groups (p
<0.0005).

Figure 4: Performance on Neuropsychological Tests in Reported v. Non-Reported OSA
Bars represent 95% CI; * denotes those with p-value <0.0005, based on Bonferroni’s correction.
Abbreviations: R-OSA – Reported OSA; nR-OSA – did not report OSA; TMT-A – Trail-making test part
A; BACS SC- Brief Assessment of Cognition in Schizophrenia Symbol Coding Subtest; HVLT- Hopkins
Verbal Learning Test; LNS- Letter-Number Sequencing; NAB – Neuropsychological Assessment Battery

In considering specific neuropsychological tests, Table 5 compares the mean Tscores and standard deviations between P-OSAv. nP-OSA for each assessment.
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Table 5: Specific Neuropsychological Test Performance in R-OSA v. nP-OSA
P-OSA

nP-OSA

p-value (only <0.05)

TMT-A (SD)

34.76 (12.94)

37.13 (13.23)

0. 000001*

BACS SC (SD)

33.70 (11.46)

35.07 (12.24)

0.002*

Category

39.97 (10.05)

40.71 (10.29)

0.049

HVLT (SD)

34.23 (7.24)

35.32 (7.89)

0.000173*

LNS (SD)

33.07 (12.43)

35.27 (12.74)

0.000002*

NAB Mazes (SD)

41.52 (7.86)

42.00 (9.25)

Fluency (SD)

* denotes p<0.005, adjusting for multiple comparisons
Abbreviations: P-OSA – Predicted OSA; nP-OSA – did not predict OSA; TMT-A – Trail-making test part
A; BACS SC- Brief Assessment of Cognition in Schizophrenia Symbol Coding Subtest; HVLT- Hopkins
Verbal Learning Test; LNS- Letter-Number Sequencing; NAB – Neuropsychological Assessment Battery;

The mean difference between P-OSA & nP-OSA TMT-A T score was -2.37 (95% CI [3.33, -1.41], with T score in P-OSA being statistically significantly lower than in nPOSA (p= 0. 000001); Cohen’s d was -0.182 (95% CI [-0.256, -0.108]). The mean
difference between P-OSA & nP-OSA BACS SC T score was -1.37, 95% CI [-2.25, 0.49], with T score in P-OSA being statistically significantly lower than in nP-OSA
(p=0.002); Cohen’s d was -0.117 (95% CI [-0.191, -0.044]). The mean difference P-OSA
& nP-OSA HVLT T score was -1.08, 95% CI [-1.65, -0.52], with T score in P-OSA being
statistically significantly lower than in nP-OSA (p= 0.000173); Cohen’s d was -0.146
(95% CI [-0.219, -0.073]). The mean difference P-OSA & nP-OSA LNS T score was 2.20, 95% CI [-3.12, -1.29], with T score in P-OSA being statistically significantly lower
than in nP-OSA (p= 0.000002); Cohen’s d was -0.176 (95% [-0.249, -0.103]). Figure 5
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illustrates average T-scores for each test, denoting statistically significant differences
between the groups (p<0.005).

Figure 5: Performance on Neuropsychological Tests in Predicted v. Non-Predicted OSA
Bars represent 95% CI; * denotes those with p-value <0.005, based on Bonferroni’s correction.
Abbreviations: P-OSA – Predicted OSA; nP-OSA – did not predict OSA; TMT-A – Trail-making test part
A; BACS SC- Brief Assessment of Cognition in Schizophrenia Symbol Coding Subtest; HVLT- Hopkins
Verbal Learning Test; LNS- Letter-Number Sequencing; NAB – Neuropsychological Assessment Battery

Specific Aim #3: Association of OSA and Functioning in Schizophrenia
After examining measures of cognition, we sought to study functional capacity
measures, specifically the UPSA-B & EFB-AF, as they related to reported and predicted
OSA. Table 6 describes performance of both measures in R-OSA v. nR-OSA and P-OSA
v. nP-OSA.
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Table 6: Functional Capacity Assessments in Reported and Predicted OSA
R-OSA

nR-OSA

p-value

UPSA-B (SD)

15.32 (2.95)

14.81 (3.17)

0.000056 **

EFB-AF (SD)

8.71 (3.7)

8.00 (4.01)

0. 000037**

P-OSA

nP-OSA

p-value

UPSA-B (SD)

14.88(3.12)

14.96 (3.10)

0.499

EFB-AF (SD)

8.02(3.99)

8.46(3.89)

0.003*

*denotes p-value < 0.005, based on Bonferroni’s correction for multiple comparisons in P-OSA. **denotes
p-value < 0.0005, based on Bonferroni’s correction for multiple comparisons in R-OSA.
Abbreviations:R-OSA—Reported OSA; nR-OSA- not reported OSA; P-OSA – Predicted OSA; np-OSA –
model did not predict OSA; UPSA-B: UCSD Performance Skills Assessment Battery- Brief ; EFB-AF –
Everyday Functioning Battery- Advanced Finances.

UPSA-B in R-OSA was statistically significantly higher than in nR-OSA (p=
0.000056). The mean difference UPSA-B score in R-OSA and nR-OSA was 0.55, 95%
CI [0.27, 0.82], Cohen’s d = 0.173 95% CI = [0.084, 0. 262]. There was no statistically
significant difference in UPSA-B between P-OSA and nP-OSA (p= 0.499). EFB-AF in
R-OSA was statistically significantly higher than in nR-OSA (p= 0. 000037). The mean
difference in EFB-AF between R-OSA and nR-OSA was 0.71, 95% CI [0.36, 1.07],
Cohen’s d =0.179, 95% CI [0.090, 0.269]. EFB-AF in P-OSA was statistically
significantly lower than in nP-OSA (p= 0.003). The mean difference in EFB-AF between
P-OSA and nP-OSA EFB-AF was -0.45, 95% CI [-0.74, -0.16], Cohen’s d = -0.112, 95%
CI [-0.186, -0.038].
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Figures 6 demonstrates the frequency distribution of UPSA-B in R-OSA v. nROSA and P-OSA v. nP-OSA. Figures 7 demonstrate the frequency distribution of EFBAF for R-OSA v. nR-OSA and P-OSA v. nP-OSA.
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Figure 6 Frequency Distribution of UPSA-B in OSA
The top graph depicts the distribution of UPSA-B in R-OSA and nR-OSA. In R-OSA, the median was
16.00 with an interquartile range of 3.00. The minimum score was 2.00 and the maximum was 20.00. In
nR-OSA, the median was 15.00 with an interquartile range of 4.00. The minimum score was 1.00 and the
maximum was 20.00. The bottom graph depicts the distribution of UPSA-B in P-OSA and nP-OSA. In POSA, the median was 15.00 with an interquartile range of 4.00. The minimum score was 1.00 and the
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maximum was 20.00. In nP-OSA, the median was 16.00 with an interquartile range of 4.00. The minimum
score was 1.00 and the maximum was 20.00.

Figure 7 Frequency Distribution of EFB-AF in OSA
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The top graph depicts the distribution of EFB-AF in R-OSA and nR-OSA. In R-OSA, the median was
10.00 with an interquartile range of 6.00. The minimum score was 0.00 and the maximum was 13.00. In
nR-OSA, the median was 9.00 with an interquartile range of 7.00. The minimum score was 0.00 and the
maximum was 13.00. The bottom graph depicts the distribution of UPSA-B in P-OSA and nP-OSA. In POSA, the median was 9.00 with an interquartile range of 7.00. The minimum score was 0.00 and the
maximum was 13.00. In nP-OSA, the median was 10.00 with an interquartile range of 6.00. The minimum
score was 0.00 and the maximum was 13.00.

Linear regression analyses were then performed to study the relationship between
OSA and each functional capacity measure (i.e., UPSA-B and EFB-AF). R-OSA had a
standardized coefficient (or Beta) of 0.061 (p= 0.000146) in association with UPSA-B in
univariate analyses; it did not maintain a statistically significant association after
controlling for sociodemographic and medical variables. P-OSA had a statistically
insignificant coefficient (or Beta) of -0.12 (p= 0.447) in association with UPSA-B in
univariate analyses. Table 7 reports multivariate linear regressions predicting UPSA-B
with R-OSA as the study variable.

Table 7: Linear Regression of UPSA-B with Reported OSA as Study Variable

R-OSA
Age
BMI
Completeness
Female
White
College
Independent Residence
Employed
Suicidal Ideation
MDD-SCID
Alogia
Avolition

Beta in
Beta in Multivariate
Univariate
Model
Model with
With R-OSA
R-OSA
0.061** ---0.125**
0.074**
0.050**
0.035
0.073**
0.159**
0.188**
0.055**
0.048
0.048
-0.090**
-0.063**
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Number of
Hospitalizations
Number of Prescriptions
Depression
Memory Loss
Benign Prostatic
Hyperplasia
Eating Disorder
Skin Cancer
MS

-0.039
-0.039
0.051
-0.034
0.055**
-0.041
0.032
-0.037

Italicized variables are medical variables based on self-report by patient.
Only statically significant variables listed above; Other variables included in multivariate model include:
Marital Status(Married), MINI-PTSD, Suicide Attempts, Flat Affect, Current Smoker, Current Drinker,
Dementia, TBI, High Cholesterol, Hypertension, TIA, Stroke, Loss of Consciousness, Epilepsy,
Osteoarthritis, Rheumatoid Arthritis, Other arthritises, Gout, Anxiety, self-reported PTSD, Bipolar
Disorder, Personality Disorder, Social Phobia, ADHD, GERD, Tinnitus, Hearing Loss, Blindness,
Glaucoma, Macular Degeneration COPD, Diabetes, Colon Cancer, Lung Cancer, Breast Cancer, Prostate
Cancer, Other Cancers, Parkinson’s Disease, Non-Migraine Headaches, Migraines, ALS,HIV.
** denotes a p-value <0.001

R-OSA had a standardized coefficient (or Beta) of 0.063 (p=0.000089) in
association with EFB-AF in univariate analyses, while P-OSA had a standardized
coefficient (or Beta) of -0.049 (p= 0.003) in association with EFB-AF. Neither R-OSA or
P-OSA maintained a significant association with EFB-AF after controlling for
sociodemographic and medical variables. Table 8 reports multivariate linear regressions
predicting EFB-AF with R-OSA and P-OSA as the study variables, respectively.

Table 8: Linear Regression of EFB-AF with Reported & Predicted OSA as Study
Variable

R-OSA
P-OSA
Age
BMI
Female
White

Beta in
Univariate
Model with ROSA
0.063**

Beta in
Multivariate
Model
With R-OSA
---0.189**
0.040
0.039
0.110**

Beta in
Univariate
Model with POSA

Beta in
Multivariate
Model with POSA

-0.049

---0.199**
--0.047
0.110**
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College
Independent
Residence
Employed
Suicidal Ideation
SCID-Depression
Alogia
Avolition
Number of
Hospitalizations
Number of
Prescriptions
Depression
Eating Disorder
Glaucoma
BPH
Rheumatoid
Arthritis
Colorectal
Cancer
Other Cancer
Loss of
Consciousness
Current Smoker

0.209**
0.174**

0.210**
0.175**

0.050**
0.051
0.033
-0.069**
-0.044
-0.044

0.050**
0.051
0.034
-0.068**
-0.044
-0.043

-0.038

-0.038

0.050
-0.067**
-0.036
0.050**
-0.053**

0.051
-0.066**
-0.037
0.051**
0.053**

----

-0.029

-0.047
0.030

-0.047
0.031

-0.035

-0.040

Italicized variables are medical variables based on self-report by patient.
Only statically significant variables listed above; Other variables included in multivariate model include:
Marital Status(Married), MINI-PTSD, Suicide Attempts, Flat Affect, Current Drinker, Dementia, TBI,
Epilepsy, Stroke, High Cholesterol, Hypertension, TIA, Osteoarthritis, Other arthritises, Gout, Anxiety,
self-reported PTSD, Bipolar Disorder, Personality Disorder, Social Phobia , ADHD, GERD, Tinnitus,
Hearing Loss, Blindness, Macular Degeneration COPD, Diabetes, Lung Cancer, Breast Cancer, Prostate
Cancer, Parkinson’s Disease, Non-Migraine Headaches, Migraines, ALS, MS,HIV.
** denotes a p-value <0.001

Exploratory Aims:
The first exploratory analyses aimed to specifically compare cognition and
functional capacity in reported versus undiagnosed (i.e., predicted-and-not-reported)
OSA in this sample. Table 9 describes CCS and performance on functional capacity
measures in three groups: Reported OSA (R-OSA), Predicted-not-reported OSA (PnROSA), and neither-predicted-nor-reported OSA (No-OSA).
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Table 9: Performance in Reported, Predicted-not-Reported, and No-OSA
R-OSA

PnR-OSA

No-OSA

CCS (SD)

37.71 (7.14)

36.07 (7.53)

37.46 (7.92)

UPSA-B (SD)

15.31 (2.93)

14.78 (3.15)

14.97 (3.08)

EFB-AF (SD)

8.76 (3.70)

7.89 (4.03)

8.46 (3.88)

Abbreviations: R-OSA—Reported OSA; PnR-OSA- predicted not reported OSA; No-OSA – neither
predicted nor reported OSA. CCS- Composite cognitive Score; UPSA-B: UCSD Performance Skills
Assessment Battery- Brief ; EFB-AF – Everyday Functioning Battery- Advanced Finances

A one-way ANOVA found statistically significant mean differences in CCS
(F(2,3788)= [18.12], p= 1.4794E-8), UPSA-B (F(2,3827)=[7.74], p= 0.000444), and
EFB-AF (F,(2,3736)=[13.01], p= 0.000002) between at least two of these three groups.
Figure 8 shows the mean CCS and 95% CI for R-OSA, PnR-OSA, and No-OSA.
Tukey’s HSD Test for multiple comparisons found that mean CCS in PnR-OSA was 1.42
(95% CI [0.72, 2.13]) T scores lower than CCS in No-OSA (p= 0.000007) and 1.71 (95%
CI [0.86, 2.56]) T scores lower than CCS in R-OSA (p= 0.000007). No statistically
significant difference between mean CCS in R-OSA and No-OSA (p= 0.769).
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Figure 8 Composite cognitive Scores in Reported, Predicted-not-Reported, and No-OSA
Mean CCS in Veterans with predicted and not reported OSA (PnR-OSA) is statistically significantly lower
than CCS in patients with reported OSA and no OSA. Error Bars represent 95% CI.

Figure 9 shows the mean UPSA-B and 95% CI for R-OSA, PnR-OSA, and NoOSA. Tukey’s HSD Test for multiple comparisons found that mean UPSA-B in PnROSA was 0.57 (95% CI [0.23, 0.92]) points lower than UPSA-B in R-OSA (p=
0.000314). No statistically significant difference was found between mean UPSA-B in
PnR-OSA and No-OSA (p= 0.277) or R-OSA and No-OSA (p=0.061).
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Figure 9 UPSA-B in Reported, Predicted-not-Reported, and No-OSA
Mean UPSA-B in Veterans with predicted and not reported OSA (PnR-OSA) is statistically significantly
lower than UPSA-B in patients with reported OSA. Error Bars represent 95% CI.

Figure 10 shows the mean EFB-AF and 95% CI for R-OSA, PnR-OSA, and NoOSA. Tukey’s HSD Test for multiple comparisons found that mean EFB-AF in PnROSA was 0.54 (95% CI [0.17, 0.91]) points lower than EFB-AF in No-OSA (p = 0.002)
and 0.83 (95% CI [0.39, 1.27]) points lower than EFB-AF in R-OSA (p= 0.000025). No
statistically significant difference was found between mean EFB-AF in R-OSA and NoOSA (p= 0.368).
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Figure 10 EFB-AF in Reported, Predicted-not-Reported, and No-OSA
Mean EFB-AF in Veterans with predicted and not reported OSA (PnR-OSA) is statistically significantly
lower than EFB-AF in patients with reported OSA and no OSA. Error Bars represent 95% CI.

The next analyses were binomial logistical regressions that aimed to identify
demographic and medical predictors of potentially undiagnosed (i.e., predicted-and-notreported) OSA. Table 10 highlights the statistically significant adjusted odds-ratios that
predict likelihood of being a Veteran with PnR-OSA or R-OSA. Overall, both groups
were associated with older age and heavier BMI. Veterans were more likely to have
reported OSA if they went to college, were married, employed, drink alcohol, had a
history of depression and PTSD, and had a higher frequency of hospitalizations and
number of prescription medications. Patients were more likely to have predicted and not
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reported OSA if they were male, unmarried, had no college education, were current
smokers, did not have history of depression, and had lower number of hospitalizations.

Table 10: Adjusted Odds-Ratios of Demographic and Medical Variables in Reported and
Undiagnosed(PnR) OSA
Age
BMI
Completeness
Female
College
Married
Employed
Smoker
Drinker
SCID-Depression
MINI-PTSD
Number of Prescriptions
Number of Hospitalizations

PnR-OSA
1.067**
1.108**
--0.133**
0.844
0.785
-2.007**
0.834
0.833
----0.873

R-OSA
1.017
1.107**
0.841
-1.458**
1.394
1.417
--1.553**
1.423
1.619**
1.398**
1.189

** denotes a p-value <0.001
Only statically significant variables listed above;Other variables included: Race-White, low annual income,
residential status (Living Independently), Alogia, Flat Affect, Avolition, Suicidal Ideation, Past Suicide
Attempt.
Abbreviations: PnR-OSA—Predicted-and-not reported OSA; R-OSA—reported OSA; SCID- Structured
Clinical Interview for DSM-IV

A final exploratory aim was to assess whether treatment for OSA in patients with
reported OSA had any association with cognition and functional capacity. Table 11
describes performance on CCS, UPSA-B, and EFB-AF in self-reported treated and
untreated OSA. No statistically significant differences were noted.

Table 11: Cognition and Functional Capacity in Treated and Untreated OSA

CCS (SD)

Treated-OSA

Untreated-OSA

p-value

37.15 (6.85)

37.92 (7.44)

0.221
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UPSA-B (SD)

15.36 (2.84)

15.23 (3.04)

0.600

EFB-AF (SD)

8.82 (3.56)

8.64 (3.80)

0.587
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DISCUSSION:
Our study described the self-reported and predicted prevalence of OSA in
schizophrenia and is the largest study to date to evaluate the association of OSA with
cognition and functional capacity in this population. Our analyses suggest that more than
80% of OSA in schizophrenia is not diagnosed with 60% of patients with schizophrenia
having undiagnosed OSA. Self-reported OSA was associated with better performance on
cognitive and functional measures, whereas predicted OSA was associated with worse
performance on these measures. This difference was likely driven by the large subsample
of predicted-and-not-reported OSA who performed worse than reported-OSA on all
measures, suggesting that the patients most vulnerable to missed OSA diagnosis have the
most significant cognitive impairments. The extent that these cognitive impairments are
caused by OSA cannot be determined from this study; however, it is notable that those
with more significant cognitive impairment have an undiagnosed, treatable illness that
could be contributing to their cognitive impairments and functional disability. Thus, the
schizophrenia patients with greatest cognitive impairment may have the most to gain
from more aggressive OSA screening, diagnosis, and treatment.

OSA is Prevalent and Highly Underdiagnosed in Schizophrenia
Our finding of self-reported OSA prevalence at 14.4% is comparable to previous
reports of OSA in schizophrenia, which range from 15-48%,7,107 and is notably higher
than historical estimates in the general population108. Our predicted prevalence at 72.1%
was outstandingly higher than reported OSA, with an estimated 60% of Veterans with
schizophrenia having undiagnosed and untreated OSA. The model we used provides a
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relatively conservative estimate of OSA as it had a specificity of 77% and sensitivity of
64.2%92; thus, there is approximately a net 10% of OSA-diagnosis that is not predicted by
the model. The model did not predict 13% of R-OSA, which represents a portion of true
OSA that was missed by the predictive model. Our findings demonstrate even more
marked discrepancies in diagnosis and high-risk or predicted status of OSA in patients
with mental illness than past work80,109,110. Our study is notably different from these past
studies in relying on self-report and lack of polysomnography, while being able to
consider a significantly larger sample size. These aforementioned studies relied on
common screening questionnaires for OSA, like STOP-BANG111, No-SAS112, NoApnea113, and Berlin Questionnaire114, which have not been validated in patients with
schizophrenia. Furthermore, one group found that these symptom-based screenings have
low specificity in patients with schizophrenia, as these symptoms often overlap with
symptoms related to schizophrenia or psychotropic medications, and recommended using
an objective metric based on BMI and neck circumference115, with nearly identical
specificity and sensitivity to the predictive model used in this study. Furthermore, the
objective variables in this model are measures that can easily be identified from the
electronic medical record and can allow for even easier screening of OSA. Symptom
based screening may however be beneficial in identifying patients with OSA that the
predictive model misses.
The high rates of predicted OSA are likely multifactorial. Known risk-factors for
OSA, like cardiovascular disease and central obesity, 116 are more prevalent in patients
with schizophrenia37,38. This can be due to genetic predispositions117, adverse metabolic
effects of second-generation antipsychotics118, and higher likelihood of engaging in
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behaviors that increase risk of OSA developing, including increased smoking, sedentary
lifestyle, and poorer eating habits119,120, many of which may be caused by negative
symptoms of their serious mental illness121. Older age is a known risk factor for OSA116
and our sample skewed older, with a mean age of approximately 55 years. Additionally,
patients with schizophrenia may show signs of accelerated or exaggerated aging 122, which
would further increase risk of OSA at younger chronologic ages. Our sample of Veterans
was almost entirely male (93%), another known risk factor for OSA. Additionally, past
work has shown that the prevalence of OSA in Veterans has been increasing over the past
decade123,124. Our findings may therefore overestimate OSA prevalence in civilian
populations of schizophrenia.

Under-diagnosis Impacts Patients with Worse Cognition & Disability
Our findings suggest that the under-diagnosis of OSA is likely non-random and
impacts patients with worse cognition and functional capacity disproportionately. Patients
with predicted OSA (P-OSA) performed worse on assessments of processing speed,
verbal learning, and working memory, domains that are known to be affected by OSA125.
Patients with P-OSA were also more likely to have no college education, be unmarried,
and have less frequent hospitalizations. Being married can be a reflection of higher
cognitive abilities126 but also increases the likelihood of witnessed apneic events or
snoring127, facilitating the diagnosis of OSA. Patients with predicted and not reported
OSA (PnR-OSA) had lower scores that those with reported-OSA (R-OSA) on CCS and
both measures of functional capacity (UPSA-B and EFB-AF), and worse than those with
No-OSA on CCS and EFB-AF. In contrast, those with R-OSA had higher composite

51

cognitive scores and performed better on functional capacity measures, showing no
statistically significant difference than patients with no predicted or reported OSA.
Patients with R-OSA even maintained a positive association with CCS after controlling
for medical comorbidities and demographics, including education, employment status,
marital status, independent living, higher rates of hospitalization and prescription
medications (all of which were notably higher in patients with R-OSA) than the rest of
the sample.
Overall, these findings suggest that those with those higher cognitive capacity are
more likely to seek care and overcome the many barriers required to confirm diagnosis of
OSA. Identified barriers to care include complex appointment schedules, transportation
difficulties, lack of understanding amongst patients and caregivers about the severity of
the problem, and the provider perception that patients cannot tolerate in-laboratory (inlab) polysomnography or use CPAP128,129. Patients with R-OSA also had positive
correlations with other diagnoses that require invasive testing and barrier, like macular
degeneration and gastrointestinal polyps. Those with less cognitive capacity may be more
likely to succumb to barriers to diagnosis and treatment, and as a result be impacted by
co-occurring medical conditions that further compromise cognition and functioning.
Our findings of functional capacity mirrored cognitive performance in reported v.
predicted OSA, though less drastically. Patients with R-OSA did better on the UPSA-B
and EFB-AF than nR-OSA, and patients with P-OSA did worse on the EFB-AF;
however, patients with P-OSA did not perform differently on the UPSA-B than nP-OSA.
Both assessments have negatively skewed distributions, suggesting a ceiling effect. Past
work have treated UPSA-B as dichotomous predictors of functioning and independent
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living101, and have found it does not predict real-word functional identifiers, like
employment status, after controlling for other variables130. In our sample, however,
employment status was not only associated with better performance on UPSA-B and
EFB-AF, but was also a significant predictor of R-OSA. This further supports the idea
that higher cognition and functioning may increase the likelihood of patients seeking and
receiving care. Neurocognitive performance, which continues to correlate with debility
from premorbid to chronic schizophrenia131, may be a more sensitive detector of
disability. Negative symptoms have been shown to mediate the relationship between
cognition and functional outcome132 and are key predictors of real-world functioning133 in
schizophrenia, rendering the UPSA-B a non-significant predictor134.

Affective Symptoms in Schizophrenia: Marker of OSA or Higher Cognition
Presence of affective and negative symptoms in this sample also demonstrated a
unique relationship with reported and predicted OSA. R-OSA was positively associated
with history of affective disorders, including past major depression and PTSD, whereas
PnR-OSA was negatively associated with a history of MDD. OSA is known to contribute
to depressive symptoms135 and past work has shown higher prevalence of OSA in
MDD88. Depression in schizophrenia is also far more prevalent than in the general
population136, but there is evidence to suggest that depressive symptoms are associated
with higher levels of cognition and functioning, and lower levels of co-occurring disease.
For example, symptoms of depression and anxiety were associated with lower rates of
metabolic syndrome, with a single point increase on the Beck Depression inventory
associated with a 5.1% decreased probability of developing metabolic syndrome in
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patients with schizophrenia137. Furthermore, expressive deficits and restrictions in
affective and emotional ranges in schizophrenia are typically associated with less
dysphoric symptoms but increased neurocognitive impairments and psychosocial
functioning32,138,139. This is supported by some of our non-primary findings, including
negative symptoms (i.e., avolition, alogia, and flat affect) having a significant negative
association with CCS, UPSA, and EFB-AF in our multivariate models while
diagnostically verified history of depression and self-reported suicidal ideation
maintained a positive association with these measures. Additionally, there were lower
rates of negative symptoms in R-OSA, particularly alogia (p=0.005), although they did
not meet the conservative threshold of statistical significance used in our analyses.

The Importance of CPAP and OSA Treatment
Exploratory analyses did not reveal a difference in cognition or functional
capacity between patients who did and did not report receiving treatment for OSA. A
major limitation in this exploratory aim is the wording of the questionnaire patients
completed. It asked the Veteran to check a box if they “take meds” for each illness; the
main treatment for OSA does not involve ‘taking meds’ and thus may have been a source
of unclarity for each participant. A small pilot study90 and additional case report140 have
previously found improvement in cognition in patients with schizophrenia who were
adherent to CPAP.
Treating OSA in schizophrenia could improve cognition, functioning, and
ultimately mortality. Undertreatment of physical co-morbidities continues to drive the
large life expectancy gap in schizophrenia141. Recent studies have shown patients with
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psychosis have comparable rates of CPAP adherence (~65% 3 months after full CPAP
trial) and improvements in apneic and hypoaneic events to the general population142,143.
Patients with schizophrenia, thus, not only tolerate OSA treatment but may have more to
gain.
CPAP adherence has been tied to improved cognition and prevention of cognitive
decline in other populations144. The effect size of P-OSA in cognition and functional
capacity from our study, ranging from -0.12 to -0.18, is small but comparable in
magnitude to improvements that can be seen with CPAP64 and CIAS34. Treating and
reversing impairments in cognition is particularly important as lower cognitive
functioning, in addition to cardiovascular disease, diabetes, and hypertension, is an
independent risk factor of mortality in serious mental illness145. Treatment of OSA can
also reduce the sympathetic activation, oxidative stress and pro-inflammatory reactions
that are a result of intermittent hypoxia seen in OSA that worsen cardiovascular disease
and psychiatric symptoms146. There is concern, however, that those that have the most to
gain (i.e., those with more severely impaired cognition) may be less adherent as a result
of being unable to identify the benefits of treatment147. Patient education, technological,
and psychosocial intervention strategies can be used to promote adherence and ensure
effective treatment.

Strengths, Limitations and Future Considerations
This thesis has many strengths and important limitations to consider. This is the
largest study to date considering the relationship between OSA and cognition and
functioning in patients with schizophrenia. This large sample size of nearly 4000
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Veterans who had undergone questionnaires and neuropsychological and functional
batteries was a very rich and robust dataset. The power afforded by working with such a
large sample allowed for particularly conservative thresholds for statistical significance.
Additionally, rigorous consideration and inclusion of co-variates in linear regression
models may contribute to an under-estimation of the unique association of OSA with
cognition and functioning. The main limitation of this study is its reliance on self-report
for medical history and treatment. This in and of itself may be a barrier for those with
worse cognition and functioning and may inaccurately reflect their medical history,
which was integral to the predictive scoring system. To account for this, we used a
‘completeness’ variable that considered how thoroughly each Veteran completed the
required portions of the questionnaires and controlled for this in our models. The
completeness variable in fact maintained a significant positive association with CCS and
UPSA-B. Additionally, It is important to note that this study was cross-sectional in
nature, and thus temporal relationships with OSA treatment and cognitive and functional
performance cannot be ascertained.
This study did not have data on Veteran sleep quantity, quality or other
characteristics that are important for the diagnosis of sleep apnea, including apneic
episodes. The clinical prediction model that we used, however, has a sensitivity and
specificity that is comparable to, if not better92 than, other symptom-driven models. The
use of such a model is particularly important in patients whose negative symptoms can
result in an inability to communicate such symptoms as excessive daytime sleepiness,
snoring, changes in concentration and mood. Nevertheless, this study is limited in its lack
of sleep symptom data; future work can explore how the presence or absence of these
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symptoms impacts diagnostic rates in this population. Another important limitation to
acknowledge is that this study was completed in the Veteran population. Veterans tend to
be older than the civilian population, disproportionately male, and have higher rates of
mental illness148,149. This may impact the generalizability of our findings to civilian
populations of schizophrenia.
Future work can further elucidate associations between OSA diagnosis, cognition
and functioning in schizophrenia. Use of polysomnography in future studies can verify
apneic-hypoapneic events and work to correlate these events with performance on
cognitive and functional capacity measures. Most importantly, future work can study the
impact of CPAP on cognition by comparing performance on neuropsychological batteries
before and after CPAP adherence in patients with schizophrenia. Additional research may
explore whether CPAP treatment benefits patients with schizophrenia differently than
others by conducting a case-control study with age- and gender-matched neurotypical
controls.

Conclusions
OSA is likely very common in patients with schizophrenia. Most of these patients,
particularly the most vulnerable with the worst cognition and functioning, may be
unaware of their diagnosis and not receiving treatment. Use of a clinical prediction model
based on quantitative measures and medical history can identify at-risk patients whose
psychiatric illness reduces reliability of symptom-driven screening. Treatment of their
OSA might improve their cognition, sleep, and physical health, which in turn could
reduce disability and mortality.
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